METTL3 acts as a tumor suppressor in renal cell carcinoma (Li et al., 2017b), while METTL3 promotes chemo‐ and radioresistance in pancreatic cancer cells and promotes breast cancer progression (Cai et al., 2018; Taketo et al., 2018). Here, METTL3 is linked to renal cell carcinoma.